Dark

Check out our Level2View

ALPMY
ASTELLAS PHARMA UNSP/ADR
stock OTC ADR

EOD

May 15, 2025

9.15USD+0.318%(+0.03)174,583

Pre-market

Dec 31, 1969

0.00USD-100.000%(-9.12)0

After-hours

Dec 31, 1969

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 17, 2021

07:03AM EST Astellas, Seagen Announce Positive CHMP Opinion For PADCEV RTTNews

06:49AM EST Astellas And Seagen Get Positive CHMP Opinion For PADCEV In Locally Advanced Or Metastatic Urothelial Cancer RTTNews

06:40AM EST Astellas and Seagen Receive Positive CHMP Opinion for PADCEV(tm) (enfortumab PR Newswire

Dec 14, 2021

08:02AM EST Astellas and MBC BioLabs Announce Future Innovator Prize Winners - Helping PR Newswire

Dec 1, 2021

08:20PM EST Astellas Pharma Inc. (ALPMY, ALPMY) and Dyno Therapeutics Inc. said that they have reach an agreement to develop next-generation adeno-associated virus or AAV vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap platform. RTTNews

08:00PM EST Astellas And Dyno Therapeutics To Develop AAV Gene Therapy Vectors For Skeletal And Cardiac Muscle RTTNews

07:00PM EST Astellas and Dyno Therapeutics Announce Research Collaboration to Develop PR Newswire

08:01AM EST from Diagnosis to Relapse - at 2021 American Society of Hematology Annual Meeting PR Newswire

Nov 3, 2021

08:02AM EDT Astellas and LabCentral Announce Future Innovator Prize Winners - Helping PR Newswire

Oct 12, 2021

08:03AM EDT Astellas Closes Enrollment In EV-103 Trial Cohort K Combining PADCEV With Pembrolizumab As Urothelial Cancer Treatment RTTNews

08:00AM EDT PADCEV(r) (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer PR Newswire

Sep 27, 2021

10:35AM EDT Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan Benzinga

03:40AM EDT Japan's Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) announced Monday that PADCEV (enfortumab vedotin) has received approval from Japan's Ministry of Health, Labour and Welfare or MHLW. The approval is for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy. The New Drug Application received priority review. RTTNews

03:03AM EDT Astellas Pharma Says Japan's MHLW Approves PADCEV For Advanced Urothelial Cancer RTTNews

03:00AM EDT Japan's MHLW Approves PADCEV(r) (enfortumab vedotin) for Advanced Urothelial PR Newswire

Sep 22, 2021

08:03AM EDT Astellas To Present Fezolinetant Findings From Phase 3 SKYLIGHT 2 Trial At North American Menopause Society Meeting RTTNews

08:03AM EDT Trial in Oral Session at The North American Menopause Society 2021 Annual Meeting PR Newswire

Sep 21, 2021

08:02AM EDT Astellas and MBC BioLabs Announce Future Innovator Prize to Help Biotech PR Newswire

Sep 17, 2021

06:05PM EDT Astellas' and Pfizer's XTANDI(r) (enzalutamide) Reduced Risk of Death by 34% in PR Newswire

Sep 14, 2021

07:50AM EDT The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga

06:48AM EDT Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold Benzinga

02:49AM EDT Astellas Pharma Inc. (ALPMY, ALPMY) said Tuesday that the ASPIRO clinical trialparticipant, whodeveloped a serious adverse event, passed away on September 9. The cause of death is still pending. RTTNews

02:27AM EDT Astellas Pharma Says Rare Neuromuscular Clinical Trialparticipant Passed Away; Cause Of Death Still Pending RTTNews

02:01AM EDT Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical PR Newswire

Sep 1, 2021

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

07:23AM EDT See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial Benzinga

02:53AM EDT Astellas Pharma Inc. (ALPMY, ALPMY) said Wednesday that it has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy. RTTNews

02:03AM EDT Astellas Updates On ASPIRO Clinical Trial Of AT132 In Patients With X-linked Myotubular Myopathy RTTNews

02:01AM EDT Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with PR Newswire

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

07:30PM EDT (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease PR Newswire

Aug 18, 2021

07:07AM EDT Astellas Partners With LabCentral To Help Emerging Biotechs Accelerate Preclinical Scientific Research RTTNews

07:00AM EDT Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate PR Newswire

Jul 28, 2021

10:14AM EDT The IPO Recap Party Is Everything But Over Benzinga

Jul 20, 2021

06:12PM EDT Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients PR Newswire

Jul 19, 2021

02:32PM EDT Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data Benzinga

Jul 12, 2021

06:48AM EDT Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer Benzinga

Jul 9, 2021

02:10PM EDT (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer PR Newswire

Jun 25, 2021

09:01AM EDT Astellas Pharma, FibroGen: CHMP Of EMA Adopted Positive Opinion Relating To Use Of Roxadustat RTTNews

08:57AM EDT Astellas Receives Positive CHMP Opinion for EVRENZO(tm) (roxadustat) for Adult PR Newswire

Jun 8, 2021

02:39AM EDT Astellas Pharma To Present New Data In Acute Myeloid Leukemia At EHA RTTNews

02:01AM EDT New Research Reflects Astellas' Commitment to Acute Myeloid Leukemia at EHA PR Newswire

May 19, 2021

05:05PM EDT (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy PR Newswire

May 17, 2021

08:06AM EDT Astellas To Present Data From Expanding Oncology Portfolio During The 2021 ASCO Annual Meeting RTTNews

08:00AM EDT Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO PR Newswire

May 13, 2021

08:00PM EDT Japan's Ministry of Health, Labour and Welfare Grants Priority Review for PR Newswire

May 11, 2021

12:32PM EDT Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows Benzinga

May 4, 2021

02:51AM EDT Astellas Pharma Inc. (ALPMY, ALPMY) said the European Commission has approved an additional indication for the oral once-daily therapy XTANDI (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer. The approval is based on results from the phase 3 ARCHES trial which evaluated enzalutamide in men with metastatic hormone-sensitive prostate cancer. RTTNews

02:32AM EDT Astellas Pharma: EC Approved XTANDI For Men With Metastatic Hormone-Sensitive Prostate Cancer RTTNews

02:01AM EDT Astellas' XTANDI(tm) (enzalutamide) Approved by European Commission for Men PR Newswire

May 3, 2021

02:48PM EDT Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics Benzinga

Apr 27, 2021

03:37PM EDT Astellas Takes $540M Impairment Charge Of $3B Audentes Buyout On Gene Therapy Trial Hold Benzinga

Apr 19, 2021

09:11AM EDT Seagen Inc. (SGEN) and Astellas Pharma Inc. said that the U.S. Food and Drug Administration has accepted two supplemental biologics license applications for padcev or enfortumab vedotin-ejfv in locally advanced or metastatic urothelial cancer. RTTNews

08:03AM EDT Astellas And Seagen Announce FDA Acceptance Of Two Supplemental Biologics License Applications For PADCEV RTTNews

08:02AM EDT License Applications for PADCEV(r) (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer PR Newswire

Apr 7, 2021

05:54AM EDT FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat Benzinga

Mar 29, 2021

10:26PM EDT Astellas Pharma Inc. (ALPMY, ALPMY) said that a phase 3 confirmatory trial of XOSPATA or gilteritinib in patients with relapsed (disease that has returned) or refractory (resistant to treatment) FLT3 mutation-positive acute myeloid leukemia or AML met its primary endpoint of overall survival compared to chemotherapy at a planned interim analysis. RTTNews

08:45PM EDT Astellas' XOSPATA Meets OS Endpoint In COMMODORE Trial Of Patients With Relapsed Or Refractory AML With FLT3 Mutation RTTNews

08:00PM EDT COMMODORE Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation PR Newswire

Mar 26, 2021

09:48AM EDT Astellas : FDA Approves Myrbetriq For Children With RTTNews

09:26AM EDT Astellas Gets Positive CHMP Opinion For XTANDI On RTTNews

09:04AM EDT Astellas Pharma Secures New Indication, New Product Formulation Approvals From FDA For Children With NDO RTTNews

09:00AM EDT Astellas Garners New Indication & New Product Formulation Approvals From U.S. PR Newswire

08:30AM EDT Astellas Receives Positive CHMP Opinion For XTANDI For Patients With Metastatic Hormone-Sensitive Prostate Cancer RTTNews

08:28AM EDT Astellas Receives Positive CHMP Opinion for XTANDI(tm) (enzalutamide) for PR Newswire

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

02:05AM EDT Astellas Pharma And Seagen: MAA For Enfortumab Vedotin Accepted By European Medicines Agency RTTNews

02:01AM EDT European Medicines Agency Accepts Marketing Authorization Application for PR Newswire

Mar 11, 2021

08:21AM EST Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer Benzinga

Feb 19, 2021

01:08PM EST Astellas Pharma's Fezolinetant Topped Placebo For Reducing Severity Of Menopausal Hot Flash In Phase 3 Studies Benzinga

08:10AM EST Astellas Announces Positive Topline Results From Phase 3 Pivotal SKYLIGHT 1, 2 Clinical Trials For Fezolinetant RTTNews

08:01AM EST Trials of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Postmenopausal Women PR Newswire

Feb 18, 2021

08:56AM EST Seagen/Astellas Pharma Seek Approval For PADCEV's Expanded Use In Urothelial Cancer Settings Benzinga

08:02AM EST Astellas And Seagen Submit Two SBLAs To FDA For PADCEV In Locally Advanced Or Metastatic Urothelial Cancer RTTNews

08:00AM EST Applications to the U.S. FDA for PADCEV(r) (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer PR Newswire

Feb 12, 2021

02:15PM EST vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy PR Newswire

02:15PM EST Advantage of PADCEV(r) (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer PR Newswire

Feb 3, 2021

10:26PM EST Astellas's XOSPATA Gets Conditional Approval In China For Relapsed Or Refractory AML With FLT3 Mutation RTTNews

10:00PM EST National Medical Products Administration for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation PR Newswire

Jan 28, 2021

01:29PM EST Astellas Achieves 100% Score on Corporate Equality Index for Seventh PR Newswire

Jan 13, 2021

07:16AM EST Actinium Pharma Announces Research Collaboration With RTTNews

07:02AM EST Actinium Announces Research Collaboration With Astellas Pharma RTTNews

07:01AM EST Actinium and Astellas Announce Research Collaboration Focused on Novel PR Newswire

Jan 6, 2021

08:10AM EST Astellas Says FDA Accepts For Priority Review NDA For Mirabegron RTTNews

08:01AM EST Oral Suspension and Supplemental New Drug Application for Myrbetriq(r) (mirabegron) Tablets in Pediatric Patients PR Newswire

Dec 27, 2020

02:34AM EST Audentes Therapeutics, an Astellas genetic medicines company, said that the U.S. Food and Drug Administration lifted the clinical hold for the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy. RTTNews

Dec 21, 2020

01:34AM EST Astellas Pharma Inc.'s (ALPMY, ALPMY) Xospata or gilteritinib plus azacitidine compared to azacitidine alone in newly diagnosed FLT3 mutation-positive acute myeloid leukemia patients who were ineligible for intensive induction chemotherapy did not meet its primary endpoint of overall survival, as per a phase 3 LACEWING trial. RTTNews

01:03AM EST Astellas Pharma Says Phase 3 Trial Of XOSPATA Plus Azacitidine Did Not Meet Endpoint Of Overall Survival RTTNews

01:00AM EST Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy PR Newswire

Dec 7, 2020

12:16AM EST KaliVir, Astellas Pharma Enter Licensing Agreement For RTTNews

12:04AM EST KaliVir Immunotherapeutics And Astellas Enter Licensing Agreement For Development Of VET2-L2 Novel Oncolytic Virus RTTNews

12:00AM EST Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus PR Newswire

Nov 27, 2020

02:31AM EST Astellas Pharma Inc. (ALPMY) and FibroGen, Inc. (FGEN) announced that Japan's Ministry of Health, Labour and Welfare approved EVRENZO (roxadustat) for the treatment of anemia of chronic kidney disease in adult patients not on dialysis. This approval triggers a milestone payment of $15 million by Astellas to FibroGen. RTTNews

02:08AM EST Astellas, FibroGen: Japan's MHLW Approved EVRENZO For Treatment Of Anemia Of CKD In Adult Patients Not On Dialysis RTTNews

02:02AM EST Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis PR Newswire

Nov 16, 2020

08:02AM EST Astellas to Present New Data on Gilteritinib in FLT3 Mutation-Positive Acute PR Newswire

Nov 6, 2020

03:11AM EST Japan-based Astellas Pharma Inc. (ALPMY) announced Friday that the China National Medical Products Administration or NMPA has approved XTANDI (enzalutamide soft capsules) to treat non-metastatic castration-resistant prostate cancer. RTTNews

02:13AM EST Astellas : XTANDI Approved By China NMPA For Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer RTTNews

02:01AM EST XTANDI(r) (enzalutamide soft capsules) Approved by China NMPA for the Treatment PR Newswire

Oct 28, 2020

08:37AM EDT Japan-based Astellas Pharma Inc. (ALPMY) said Wednesday that the U.S. Food and Drug Administration or FDA has granted Fast Track designation for the development of ASP5354, based on non-clinical and clinical data. RTTNews

08:03AM EDT Astellas Receives U.S. FDA Fast Track Designation For ASP5354 RTTNews

Oct 20, 2020

08:17AM EDT Astellas Pharma Inc. (ALPMY, ALPMY) announced that the FDA has granted Fast Track designation for the development of ASP0367/MA-0211 as a potential treatment for primary mitochondrial myopathies. There is no FDA-approved treatment for primary mitochondrial myopathies, a rare disease with a high unmet medical need. RTTNews

08:10AM EDT Astellas Pharma: FDA Grants Fast Track Designation For ASP0367/MA-0211 RTTNews

08:02AM EDT Modulator being Developed for the Treatment of Primary Mitochondrial Myopathies PR Newswire

Oct 19, 2020

03:12AM EDT Astellas Pharma: Roxadustat Data In Anemia Of Chronic Kidney Disease To Be Released At ASN Kidney Week 2020 Reimagined RTTNews

03:00AM EDT New Roxadustat Data in Anemia of Chronic Kidney Disease to be Released at ASN PR Newswire

Oct 12, 2020

07:56AM EDT Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) announced results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial saying that durable responses were observed in patients who had previously received immunotherapy but were ineligible for cisplatin in locally advanced or metastatic setting. RTTNews

06:51AM EDT Astellas, Seagen Announce Positive Topline Results From Second Cohort Of Patients In Phase 2 Pivotal Trial Of PADCEV RTTNews

06:45AM EDT Patients in Phase 2 Pivotal Trial of PADCEV(r) (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer PR Newswire

Sep 29, 2020

08:02AM EDT Astellas and MBC BioLabs Announce Golden Ticket Competition to Help Biotech PR Newswire

Sep 28, 2020

01:04AM EDT Astellas Pharma Announces Findings From Two Real-World Evidence Studies And A Qualitative Sleep Survey RTTNews

01:01AM EDT Astellas' Real-World Evidence Studies Provide Further Insight into Negative PR Newswire

Sep 18, 2020

07:16AM EDT Biotechnology company Seattle Genetics, Inc. (SGEN) and Japanese pharmaceutical company Astellas Pharma Inc. (ALPMY, ALPMY) announced Friday that a phase 3 trial of PADCEV (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy. RTTNews

06:51AM EDT Seattle Genetics And Astellas Pharma Announce Phase 3 Trial Of PADCEV Meets Primary Endpoint RTTNews

06:45AM EDT Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer PR Newswire

Jul 22, 2020

09:00AM EDT Fund Early Clinical Studies of ASP8062 to Investigate Potential Novel Therapeutic Approach to Address the Opioid Crisis PR Newswire

Share